+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type (Antibiotic, Anticholinergic, Beta2-agonists), Product (Inhalers, Nebulizers), Test, Application - Forecast 2024-2030- Product Image
Global Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type (Antibiotic, Anticholinergic, Beta2-agonists), Product (Inhalers, Nebulizers), Test, Application - Forecast 2024-2030- Product Image
Sale

Global Chronic Obstructive Pulmonary Disease Treatment Market by Drug Type (Antibiotic, Anticholinergic, Beta2-agonists), Product (Inhalers, Nebulizers), Test, Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 185 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5337882
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Obstructive Pulmonary Disease Treatment Market size was estimated at USD 77.50 billion in 2023, USD 83.39 billion in 2024, and is expected to grow at a CAGR of 7.69% to reach USD 130.24 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Chronic Obstructive Pulmonary Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Chronic Obstructive Pulmonary Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Chronic Obstructive Pulmonary Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adamis Pharmaceuticals Corporation, Almirall, S.A., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Orion Oyj, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Chronic Obstructive Pulmonary Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Antibiotic
    • Anticholinergic
    • Beta2-agonists
    • Methylxanthines
    • Oral Corticosteroid
    • Phosphodiesterase-4 Inhibitors
  • Product
    • Inhalers
    • Nebulizers
  • Test
    • Arterial Blood Gas Test
    • Chest X-ray Test
    • CT scan
    • Genetic Test
    • Lung Functional Test
  • Application
    • Chronic Bronchitis
    • Emphysema
    • Refractory Asthma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Chronic Obstructive Pulmonary Disease Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Chronic Obstructive Pulmonary Disease Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Chronic Obstructive Pulmonary Disease Treatment Market?
  4. What is the market share of the leading vendors in the Chronic Obstructive Pulmonary Disease Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Chronic Obstructive Pulmonary Disease Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Chronic Obstructive Pulmonary Disease Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in geriatric population and rise in unhealthy lifestyle
5.1.1.2. Geoing number of asthma and chronic obstructive pulmonary disease (COPD)
5.1.1.3. Increasing consumer awareness toward digital asthma care devices
5.1.2. Restraints
5.1.2.1. Stringent regulations for inhaler approvals by the government
5.1.3. Opportunities
5.1.3.1. Rapid technological advancements and new product launches in the asthma devices
5.1.3.2. High demand for home care therapeutic devices
5.1.4. Challenges
5.1.4.1. Increased pricing pressures and patent expiries on inhalers
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Type
6.1. Introduction
6.2. Antibiotic
6.3. Anticholinergic
6.4. Beta2-agonists
6.5. Methylxanthines
6.6. Oral Corticosteroid
6.7. Phosphodiesterase-4 Inhibitors
7. Chronic Obstructive Pulmonary Disease Treatment Market, by Product
7.1. Introduction
7.2. Inhalers
7.3. Nebulizers
8. Chronic Obstructive Pulmonary Disease Treatment Market, by Test
8.1. Introduction
8.2. Arterial Blood Gas Test
8.3. Chest X-ray Test
8.4. CT scan
8.5. Genetic Test
8.6. Lung Functional Test
9. Chronic Obstructive Pulmonary Disease Treatment Market, by Application
9.1. Introduction
9.2. Chronic Bronchitis
9.3. Emphysema
9.4. Refractory Asthma
10. Americas Chronic Obstructive Pulmonary Disease Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Adamis Pharmaceuticals Corporation
14.1.3. Almirall, S.A.
14.1.4. Astellas Pharma Inc.
14.1.5. AstraZeneca PLC
14.1.6. Bayer AG
14.1.7. Boehringer Ingelheim Pharmaceuticals, Inc.
14.1.8. Chiesi Farmaceutici S.p.A.
14.1.9. F. Hoffmann-La Roche Ltd.
14.1.10. GlaxoSmithKline Plc
14.1.11. Johnson & Johnson Services, Inc.
14.1.12. Merck & Co., Inc.
14.1.13. Novartis AG
14.1.14. Orion Oyj
14.1.15. Sunovion Pharmaceuticals Inc.
14.1.16. Teva Pharmaceutical Industries Ltd.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET DYNAMICS
FIGURE 7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 10. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2030 (%)
FIGURE 12. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY BETA2-AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY METHYLXANTHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 13. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 16. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ARTERIAL BLOOD GAS TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHEST X-RAY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY LUNG FUNCTIONAL TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REFRACTORY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 40. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 41. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 44. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 45. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 54. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 59. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 63. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 67. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 71. INDONESIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 75. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 78. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 79. MALAYSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 83. PHILIPPINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 87. SINGAPORE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 91. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 95. TAIWAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 99. THAILAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 102. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 103. VIETNAM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 112. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 115. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 116. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 120. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 123. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 124. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 131. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 132. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 136. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 139. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 144. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 147. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 148. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 150. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 151. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 152. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 155. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 156. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 179. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 180. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 184. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 194. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 195. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Adamis Pharmaceuticals Corporation
  • Almirall, S.A.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Chiesi Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Oyj
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 83.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 130.24 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Global Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class (Bronchodilators, Combination, Corticosteroids), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Forecast 2024-2030 - Product Image

Global Chronic Obstructive Pulmonary Disease Therapeutics Market by Drug Class (Bronchodilators, Combination, Corticosteroids), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Forecast 2024-2030

  • Report
  • 197 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment: Global Strategic Business Report - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment: Global Strategic Business Report

  • Report
  • 299 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Forecast 2023-2030 - Product Image

Global Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Forecast 2023-2030

  • Report
  • 184 Pages
  • Global
From
Global Chronic Obstructive Pulmonary Disease Therapeutics Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis - Product Image

Global Chronic Obstructive Pulmonary Disease Therapeutics Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • Report
  • 220 Pages
  • Global
From

About the Chronic Obstructive Pulmonary Disease Drug Market

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions. The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.